Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,620.21 103.94 0.72%
TOPIX 1,179.90 6.53 0.56%
HANG SENG 22,760.24 64.23 0.28%

Through 2021, Major Constraints in the Hospital-Treated Infections Drug Market Will Include the Loss of Patent Protection for



  Through 2021, Major Constraints in the Hospital-Treated Infections Drug
  Market Will Include the Loss of Patent Protection for Key Branded
  Products—Notably Pfizer’s Zyvox—and Continued Generic Erosion of
  Premium-Priced Agents Such as Meropenem

   Infectious Disease Physicians Want New Therapies that are Active Against
    Multidrug-Resistant Gram-Negative Bacteria, According to Findings from
                              Decision Resources

Business Wire

BURLINGTON, Mass. -- December 03, 2012

Decision Resources, one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that, in the hospital-treated
infections (HTI) drug market, the loss of patent protection for key branded
products—notably Pfizer’s Zyvox, the HTI sales leader in 2011—and the
continued generic erosion of premium-priced agents such as meropenem (Cubist
Pharmaceuticals/AstraZeneca’s Merrem/Meronem; Dainippon Sumitomo’s Meropen;
generics) as well as increasingly stringent regulatory and reimbursement
environments will be the major constraints of market growth through 2021.

The Pharmacor advisory service entitled Hospital-Treated Infections finds
that, over the next decade, the HTI market will grow at a modest 2.7 percent
annual rate in the United States, France, Germany, Italy, Spain, the United
Kingdom and Japan. This growth will be driven primarily by the uptake of 12
emerging therapies and continued use of premium-priced agents that target
multidrug-resistant (MDR) pathogens.

The HTI market is currently dominated by parenteral agents, and drug
developers recognize the need for more-convenient dosing, either in the form
of oral formulations or drugs that require less frequent administration. This
convenience would facilitate early patient discharge, thereby reducing
hospital and patient costs. Five of the emerging therapies slated to launch by
2021—Rib-X’s delafloxacin, Furiex’s JNJ-Q2, Trius/Bayer’s tedizolid,
Tetraphase’s eravacycline and Nabriva/Forest’s BC-3781—are being developed in
both intravenous and oral formulations. Additionally, long-acting therapies
such as Durata’s dalbavancin and The Medicines Company’s oritavancin have the
potential for once-a-week dosing and would enable convenient outpatient
parenteral antibiotic therapy.

The findings also reveal that, because of the increasing prevalence and
severity of infections due to MDR gram-negative bacteria, infectious disease
physicians have called for new therapies that are active against these
pathogens. There is a growing need for antibiotics that target pathogens that
express beta-lactamases, including extended-spectrum beta-lactamases (ESBLs),
Klebsiella pneumoniae carbapenemases (KPCs), and metallo-beta-lactamases. Two
antipseudomonal cephalosporin/beta-lactamase inhibitor combinations will
launch during the forecast period: Cubist’s CXA-201 and AstraZeneca/Forest’s
CAZ-AVI.

“CXA-201 and CAZ-AVI provide broad-spectrum, gram-negative coverage and
stability against ESBLs and CAZ-AVI has the added advantage of expanded
coverage of some class C beta-lactamases and the class A carbapenemases KPC,”
said Decision Resources Analyst Maria Ascano, Ph.D. “According to infectious
disease experts we interviewed, when approved, both agents are likely to
partly replace carbapenems for treatment of MDR-gram-negative pathogens,
thereby stemming emergence of carbapenem resistance.”

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
       trademarks or registered trademarks of their respective holders.

Contact:

Decision Resources
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement